The University of Queensland (UQ), Australia, has announced impressive pre-clinical results for its Covid-19 vaccine, one of the first candidates to receive funding from the  Coalition for Epidemic Preparedness Innovation (CEPI).

The results showed the vaccine was able to raise significant antibodies to neutralise the virus. The UQ team had decided to prioritise getting robust pre-clinical data before progressing the vaccine to human, clinical trials.

They were supported in this part of their development by the Peter Doherty Institute for Infection and Immunity.

UQ project co-leader professor Paul Young commented: “This is what we were hoping for, and it’s a great relief for the team given the tremendous faith placed in our technology by CEPI, Federal and Queensland Governments and our philanthropic partners.

“We were particularly pleased that the strength of the antibody response was even better than those observed in samples from COVID-19 recovered patients,” who have natural immunity to the virus.”

University of Melbourne and Doherty Institute professor Kanta Subbarao added that the high-level of neutralising antibodies “is a very important finding because similar immune responses with SARS vaccines in animal models were shown to lead to protection from infection.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.